TheEdgeResearch
Home / Stocks / ZTS

Zoetis Inc. (ZTS)

NYSE Healthcare Drug Manufacturers - Specialty & Generic
$71.56 ▲ +0.22%
Market Cap
$30.00B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.73
52-Wk Range
70.26-148.79
CEO
Kristin C. Peck
Country
US
Currency
USD

Zoetis Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Parsippany, NJ, US. The stock last traded at $71.56, up 0.22% on the session, giving a market capitalisation of $30.00B. On trailing twelve-month figures it carries a trailing P/E of 11.77, a net margin of 27.5%. Its beta of 0.73 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
11.77
Price / Sales
3.15
Price / Book
9.49
EV / EBITDA
9.75
Gross margin
70.9%
Operating margin
37.0%
Net margin
27.5%
Return on equity
Debt / equity
2.93
Current ratio
3.08
Dividend yield
2.9%
Payout ratio
34.0%
Company profile
Exchange
New York Stock Exchange
Employees
14,500
IPO date
2013-02-01
Headquarters
Parsippany, NJ, US
About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Comparable companies

Zoetis Inc. is most often compared with the following Healthcare names:

ARGXBDXCICORELANELVHLNIDXXREGNTAK
More research on ZTS
ZTS technical analysis ZTS TheEdge Score Compare against peers
Open full interactive analysis & DCF →